Henry Schein (NASDAQ:HSIC) Stock Price Expected to Rise, BTIG Research Analyst Says

Henry Schein (NASDAQ:HSIC) had its target price increased by equities researchers at BTIG Research from $100.00 to $110.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 23.28% from the stock’s previous close.

HSIC has been the subject of several other reports. Barclays reiterated an “overweight” rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Stifel Nicolaus set a $95.00 price objective on Henry Schein in a report on Wednesday, August 5th. BMO Capital Markets started coverage on Henry Schein in a research report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective on the stock. Barrington Research set a $104.00 target price on Henry Schein in a report on Wednesday, August 5th. Finally, UBS Group set a $94.00 target price on Henry Schein and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Henry Schein has a consensus rating of “Hold” and a consensus target price of $92.93.

Henry Schein Trading Down 0.3%

HSIC opened at $89.23 on Wednesday. The company has a market cap of $9.94 billion, a P/E ratio of 26.01, a PEG ratio of 1.71 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 0.73 and a debt-to-equity ratio of 0.60. The company’s 50 day moving average is $85.22 and its 200-day moving average is $79.26. Henry Schein has a 1-year low of $61.94 and a 1-year high of $92.18.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The business had revenue of $3.46 billion during the quarter, compared to analysts’ expectations of $3.37 billion. During the same period in the prior year, the company earned $1.10 EPS. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities research analysts predict that Henry Schein will post 5.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently modified their holdings of HSIC. Heartland Advisors Inc. bought a new stake in shares of Henry Schein during the 4th quarter valued at about $9,070,000. Buckland Partners Management Co LLC bought a new position in shares of Henry Schein during the 2nd quarter worth approximately $1,036,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Henry Schein by 10,448.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 42,193 shares of the company’s stock worth $3,189,000 after buying an additional 41,793 shares in the last quarter. K.J. Harrison & Partners Inc acquired a new stake in shares of Henry Schein during the 1st quarter worth approximately $1,253,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Henry Schein by 15.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 115,279 shares of the company’s stock valued at $8,856,000 after acquiring an additional 15,765 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.